Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells $10,016,587.82 in Stock
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
Dianthus Therapeutics Has Appreciated 13-Fold Over Two Years. What's Going On?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Citigroup Inc. Has $2.70 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last?
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $4,158,442.34 in Stock
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics to Participate in Four Investor Conferences During November
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting